+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Drug Discovery Outsourcing Market by Service Type, Discovery Phase, Workflow, Drug Type, Application Area, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715771
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Drug Discovery Outsourcing Market grew from USD 3.96 billion in 2024 to USD 4.29 billion in 2025. It is expected to continue growing at a CAGR of 8.44%, reaching USD 6.45 billion by 2030.

Navigating the New Horizon of Drug Discovery Outsourcing

Over the last decade, pharmaceutical research and development has faced escalating complexity, soaring costs, and intensifying time-to-market pressures. Strategic outsourcing of drug discovery functions has emerged as a vital mechanism for controlling capital expenditure and accelerating pipeline progression. By partnering with specialized service providers, organizations can leverage advanced capabilities in assay development, chemical synthesis, bioinformatics, and process research without the burden of extensive in-house infrastructure. This shift has redefined traditional R&D models and ushered in an era of collaborative innovation.

Global networks of contract research organizations and technology vendors now span biological services such as assay development and biological testing, chemical offerings including custom synthesis and process R&D, and comprehensive data management solutions covering bioinformatics and data integration. These partnerships empower biotechnology and pharmaceutical companies to redirect their internal focus toward high-value activities such as target identification and compound optimization, while relying on expert providers to deliver core technical support.

This executive summary distills the pivotal trends, regulatory impacts, segmentation dynamics, regional nuances, and key corporate activities shaping drug discovery outsourcing. Drawing upon rigorous research methodology, the following pages offer decision-makers a concise yet thorough overview of the market landscape, equipping them with the insights needed to navigate uncertainty and capitalize on emerging opportunities.

Unpacking the Transformative Shifts Reshaping the Outsourcing Landscape

In recent years, the drug discovery outsourcing ecosystem has undergone a fundamental transformation driven by digital innovation, artificial intelligence integration, and shifting regulatory frameworks. The adoption of machine learning algorithms for structure-based drug design and predictive toxicology has accelerated early-stage screening processes, enabling unprecedented throughput and data fidelity. Simultaneously, cloud-based data integration platforms have democratized access to vast genomic and proteomic datasets, fostering collaborative workflows between sponsors and service providers. Regulatory agencies have responded by implementing guidelines that emphasize transparency, data integrity, and patient safety, thus elevating quality assurance standards across outsourcing partnerships.

Emerging trends such as decentralized virtual laboratories and remote monitoring solutions have unlocked new levels of flexibility in preclinical development. Providers are now deploying Internet of Things-enabled instruments and secure data pipelines to deliver real-time insights on assay performance and compound progression. Meanwhile, strategic consolidation through mergers, acquisitions, and global alliances has broadened the service portfolios of leading contract research organizations, enabling a seamless continuum from target discovery to candidate optimization.

As governments worldwide champion public-private collaborations and incentivize innovation ecosystems, outsourcing models continue to evolve. Start-ups and biotech firms benefit from incubator programs and translational research grants, while large pharmaceutical enterprises increasingly rely on hybrid onshore-offshore frameworks to balance regulatory compliance with cost efficiencies. These transformative shifts underline the growing sophistication of a marketplace that is no longer defined solely by price, but by speed, quality, and technological capability.

Assessing the Cumulative Impact of US Tariffs on Outsourced Drug Discovery

The introduction of cumulative tariffs on imported pharmaceutical reagents, instruments, and raw materials in the United States by 2025 has recalibrated cost structures within outsourced drug discovery operations. Historically reliant on competitive pricing from offshore suppliers, many contract research organizations have faced margin erosion as duty burdens rose on high-value chemical intermediates and biologics reagents. This trend has brought about a chain reaction, prompting providers to reassess sourcing strategies by diversifying supplier networks and negotiating volume-based agreements to mitigate tariff exposure.

Beyond raw material costs, equipment manufacturers have passed on additional expenses in analytical instrumentation and automated screening platforms, leading to higher capital leases and service fees for end users. In response, outsourcing clients have sought fixed-cost contracts and performance-based pricing models to hedge against future tariff escalations. The uncertainty surrounding trade policies has also accelerated the repatriation of certain research activities to domestic sites, where tariff liabilities are minimized, but operational overheads may be higher. This onshore shift carries implications for workforce distribution, infrastructure investment, and project timelines.

Amid these challenges, savvy organizations are leveraging regional free-trade agreements and bonded warehouse facilities to optimize logistics. They are investing in local manufacturing capacities for critical reagents and partnering with compliant suppliers that maintain strategic stockpiles. These adaptive measures are essential for preserving program continuity, ensuring regulatory alignment, and sustaining innovation throughput in an environment of elevated cross-border cost pressures.

Illuminating the Market Through Comprehensive Segmentation Insights

A granular analysis of the market through service type reveals that biological services dominate high-throughput assay development and biological testing engagements, while chemical services-encompassing custom synthesis and process R&D-remain essential for hit-to-lead activities. Data management services, unified under bioinformatics and data integration, are gaining prominence as digital ecosystems become integral to every phase of discovery.

When viewed through the lens of discovery phase, lead optimization activities comprise compound screening and structure-based drug design, drawing on advanced computational modeling and high-content screening platforms to refine candidate profiles. Target identification efforts leverage biomarker discovery and genomic sequencing methods to unveil novel therapeutic pathways, driving precision medicine initiatives and companion diagnostic development.

An examination of workflow segmentation highlights the continuous progression from lead identification and candidate optimization to preclinical development, with intervening stages of target identification, screening, validation, and functional informatics underscoring the end-to-end nature of outsourced partnerships. This integrated approach facilitates smoother project handoffs and data harmonization across disparate research teams.

Differentiating by drug type, large molecules-including biologics and biosimilars-have spurred demand for specialized cell line development, high-throughput bioprocessing, and regulatory compliance support. Small molecules continue to benefit from custom synthetic routes and process intensification strategies that enhance yield and purity.

Application area segmentation indicates that oncology outsourcing commands significant share, driven by the complexity of hematological malignancies and solid tumors, while cardiovascular disease research focuses on heart failure and hypertension. Infectious disease initiatives targeting bacterial and viral infections have surged, reflecting global public health priorities.

Finally, end user segmentation shows that contract research organizations, both full-service and specialty, remain primary providers, whereas pharmaceutical and biotechnology companies-ranging from large enterprises to SMEs-outsource niche functions to accelerate development. Research institutes, including academic institutions and government research centers, leverage outsourcing to access proprietary technologies and bolster translational research efforts.

Decoding Regional Nuances Driving Outsourced Drug Discovery Demand

The Americas continue to lead in outsourcing volume, underpinned by a robust network of contract research organizations, abundant venture capital funding, and a regulatory environment that supports translational research. Key innovation hubs in North America facilitate seamless collaboration between sponsors and service providers, with an emphasis on cutting-edge assay technologies and biologics development. Meanwhile, Latin American markets are emerging as cost-competitive alternatives for early-stage activities, offering favorable labor rates and growing scientific talent pools.

Europe, Middle East & Africa present a heterogeneous landscape of mature markets in Western Europe, characterized by stringent regulatory standards and premium pricing for high-quality services. In contrast, Eastern European and Middle Eastern centers are gaining traction as nearshore destinations that blend skilled workforces with competitive cost structures. Across the region, harmonized regulatory frameworks and pan-regional clinical trial networks enable efficient knowledge sharing and multi-site study execution.

Asia-Pacific exhibits rapid growth driven by government incentives, expanding biopharma sectors, and a growing base of specialized service providers. China and India dominate in chemical synthesis and small molecule R&D due to established manufacturing infrastructure, while Southeast Asian nations are investing in advanced biologics capabilities and bioinformatics platforms. The region’s commitment to digital transformation and emerging partnerships between local firms and global sponsors underscores its strategic importance in future outsourcing strategies.

Profiling Leading Innovators Shaping the Outsourcing Ecosystem

Several leading contract research organizations have solidified their market positions through strategic acquisitions that expand service portfolios from in vitro screening to integrated bioprocessing capabilities. Their investments in modular laboratory facilities and advanced automation have shortened project lead times while maintaining high quality standards. By cultivating partnerships with technology vendors, these providers continuously upgrade their platforms for high-content imaging, single-cell analysis, and AI-driven target identification.

Pharmaceutical and biotechnology companies are increasingly forming co-development alliances with specialized service firms to de-risk early-stage programs. These collaborations often involve shared funding models and milestone-based payments, aligning incentives between sponsor and provider. Bio-pharma players are also establishing in-house incubators and joint innovation centers to facilitate real-time knowledge transfer, accelerate scale-up processes, and improve regulatory compliance through integrated quality systems.

Research institutes and academic centers contribute to the outsourcing ecosystem by licensing proprietary assays, novel screening libraries, and unique animal models. They engage with commercial partners to translate preclinical findings into viable drug candidates, leveraging contract research services to overcome capacity constraints. This synergy between academia and industry fosters a steady pipeline of early-stage assets and best practices in reproducible research methodologies.

Strategic Recommendations to Elevate Outsourced Drug Discovery Initiatives

Industry leaders should invest strategically in digital and artificial intelligence platforms that integrate seamlessly with existing workflows. By adopting cloud-native architectures and secure data lakes, organizations can accelerate hypothesis generation, improve decision-making accuracy, and reduce cycle times for compound progression.

Diversification of the global supply chain is essential to mitigate geopolitical and tariff-related risks. Establishing multi-regional sourcing agreements and forging alliances with local manufacturers for critical reagents can safeguard project continuity. Additionally, hybrid onshore-offshore frameworks should be designed to optimize regulatory compliance without sacrificing cost efficiencies.

Collaboration models must evolve toward value-based partnerships where payment structures align with performance metrics. Emphasizing transparent communication, joint governance committees, and shared risk-reward mechanisms will foster higher accountability and drive innovation. Leaders who champion a culture of continuous improvement, cross-functional training, and interdisciplinary collaboration will be best positioned to deliver next-generation therapies.

Rigorous Research Methodology Underpinning Market Intelligence

This research leverages a hybrid methodology combining primary and secondary sources to ensure comprehensive market coverage. Primary data was gathered through structured interviews with senior executives at contract research organizations, pharmaceutical sponsors, and technology vendors, offering firsthand insights into outsourcing strategies, investment priorities, and operational challenges.

Secondary research included an exhaustive review of peer-reviewed journals, regulatory publications, industry white papers, and proprietary databases. Quantitative data points were validated through triangulation techniques, cross-referencing multiple independent sources to enhance reliability.

The segmentation framework was developed through iterative consultations with subject matter experts, ensuring that service type, discovery phase, workflow, drug type, application area, and end user dimensions accurately reflect market realities. Regional analyses incorporated economic indicators, trade policies, and infrastructure assessments to highlight growth corridors and risk factors.

Quality assurance measures, including peer reviews and methodology audits, were instituted at every stage of the research process. This rigorous approach underpins the credibility of the insights presented and enables stakeholders to make confident strategic decisions.

Concluding Perspectives on the Future of Outsourced Drug Discovery

The drug discovery outsourcing landscape stands at a transformative juncture, shaped by technological breakthroughs, shifting regulatory mandates, and evolving global trade policies. Organizations that embrace digital capabilities, diversify their supply chains, and foster collaborative value models will secure a competitive advantage in accelerating therapeutic innovation. The insights distilled in this executive summary provide a roadmap for navigating complexity and capitalizing on emerging trends.

As the ecosystem matures, the lines between sponsor and service provider blur, giving rise to integrated platforms that offer end-to-end solutions. Decision-makers must remain vigilant to geopolitical shifts, tariff developments, and disruptive technologies that can rapidly alter cost structures and operational paradigms.

Ultimately, success in outsourced drug discovery will hinge on the ability to blend scientific rigor with agile business models. By aligning strategic objectives with robust data, transparent partnerships, and a commitment to continuous improvement, industry leaders can drive sustainable growth and deliver life-changing therapies to patients worldwide.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Service Type
    • Biological Services
      • Assay Development
      • Biological Testing
    • Chemical Services
      • Custom Synthesis
      • Process R&D
    • Data Management Services
      • Bioinformatics
      • Data Integration
  • Discovery Phase
    • Lead Optimization
      • Compound Screening
      • Structure-Based Drug Design
    • Target Identification
      • Biomarker Discovery
      • Genomic Sequencing Methods
  • Workflow
    • Lead Identification & Candidate Optimization
    • Preclinical Development
    • Target Identification & Screening
    • Target Validation & Functional Informatics
  • Drug Type
    • Large Molecules
      • Biologics
      • Biosimillar
    • Small Molecules
  • Application Area
    • Cardiovascular Diseases
      • Heart Failure
      • Hypertension
    • Infectious Diseases
      • Bacterial Infections
      • Viral Infections
    • Oncology
      • Hematological Malignancies
      • Solid Tumors
  • End User
    • Contract Research Organizations
      • Full-Service CROs
      • Specialty CROs
    • Pharmaceutical & Biotechnology Companies
      • Large Enterprises
      • SMEs
    • Research Institutes
      • Academic Institutions
      • Government Research Centers
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Agilent Technologies Inc.
  • Aragen Life Sciences Ltd.
  • BPS Bioscience, Inc.
  • Celentyx Ltd.
  • Charles River Laboratories International, Inc.
  • Covance, Inc.
  • Crown Bioscience, Inc.
  • Curia Global, Inc.
  • Dalton Pharma Services
  • Eurofins Scientific
  • Evotec SE
  • Explicyte
  • GenScript Biotech Corporation
  • HD Biosciences Co., Ltd.
  • IQVIA
  • Jubilant Biosys Ltd.
  • Laboratory Corporation of America Holdings
  • Merck & Co., Inc.
  • Oncodesign Services
  • Personalis, Inc.
  • Pfizer Inc.
  • PPD Inc.
  • Promega Corporation
  • Revvity Discovery Limited
  • Sanofi S.A.
  • STC Biologics Inc.
  • Syngene International Ltd.
  • TCG Lifesciences Pvt. Limited
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drug Discovery Outsourcing Market, by Service Type
8.1. Introduction
8.2. Biological Services
8.2.1. Assay Development
8.2.2. Biological Testing
8.3. Chemical Services
8.3.1. Custom Synthesis
8.3.2. Process R&D
8.4. Data Management Services
8.4.1. Bioinformatics
8.4.2. Data Integration
9. Drug Discovery Outsourcing Market, by Discovery Phase
9.1. Introduction
9.2. Lead Optimization
9.2.1. Compound Screening
9.2.2. Structure-Based Drug Design
9.3. Target Identification
9.3.1. Biomarker Discovery
9.3.2. Genomic Sequencing Methods
10. Drug Discovery Outsourcing Market, by Workflow
10.1. Introduction
10.2. Lead Identification & Candidate Optimization
10.3. Preclinical Development
10.4. Target Identification & Screening
10.5. Target Validation & Functional Informatics
11. Drug Discovery Outsourcing Market, by Drug Type
11.1. Introduction
11.2. Large Molecules
11.2.1. Biologics
11.2.2. Biosimillar
11.3. Small Molecules
12. Drug Discovery Outsourcing Market, by Application Area
12.1. Introduction
12.2. Cardiovascular Diseases
12.2.1. Heart Failure
12.2.2. Hypertension
12.3. Infectious Diseases
12.3.1. Bacterial Infections
12.3.2. Viral Infections
12.4. Oncology
12.4.1. Hematological Malignancies
12.4.2. Solid Tumors
13. Drug Discovery Outsourcing Market, by End User
13.1. Introduction
13.2. Contract Research Organizations
13.2.1. Full-Service CROs
13.2.2. Specialty CROs
13.3. Pharmaceutical & Biotechnology Companies
13.3.1. Large Enterprises
13.3.2. SMEs
13.4. Research Institutes
13.4.1. Academic Institutions
13.4.2. Government Research Centers
14. Americas Drug Discovery Outsourcing Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Drug Discovery Outsourcing Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Drug Discovery Outsourcing Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Agilent Technologies Inc.
17.3.2. Aragen Life Sciences Ltd.
17.3.3. BPS Bioscience, Inc.
17.3.4. Celentyx Ltd.
17.3.5. Charles River Laboratories International, Inc.
17.3.6. Covance, Inc.
17.3.7. Crown Bioscience, Inc.
17.3.8. Curia Global, Inc.
17.3.9. Dalton Pharma Services
17.3.10. Eurofins Scientific
17.3.11. Evotec SE
17.3.12. Explicyte
17.3.13. GenScript Biotech Corporation
17.3.14. HD Biosciences Co., Ltd.
17.3.15. IQVIA
17.3.16. Jubilant Biosys Ltd.
17.3.17. Laboratory Corporation of America Holdings
17.3.18. Merck & Co., Inc.
17.3.19. Oncodesign Services
17.3.20. Personalis, Inc.
17.3.21. Pfizer Inc.
17.3.22. PPD Inc.
17.3.23. Promega Corporation
17.3.24. Revvity Discovery Limited
17.3.25. Sanofi S.A.
17.3.26. STC Biologics Inc.
17.3.27. Syngene International Ltd.
17.3.28. TCG Lifesciences Pvt. Limited
17.3.29. Thermo Fisher Scientific Inc.
17.3.30. WuXi AppTec Co., Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. DRUG DISCOVERY OUTSOURCING MARKET MULTI-CURRENCY
FIGURE 2. DRUG DISCOVERY OUTSOURCING MARKET MULTI-LANGUAGE
FIGURE 3. DRUG DISCOVERY OUTSOURCING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DRUG DISCOVERY OUTSOURCING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CUSTOM SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS R&D, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA INTEGRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COMPOUND SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STRUCTURE-BASED DRUG DESIGN, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GENOMIC SEQUENCING METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & CANDIDATE OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET VALIDATION & FUNCTIONAL INFORMATICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOSIMILLAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULL-SERVICE CROS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SPECIALTY CROS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 103. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 104. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 105. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 106. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 107. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
TABLE 108. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 109. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 110. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 111. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 112. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 113. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 114. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 115. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 116. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 117. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 119. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 120. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 121. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 122. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 123. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 124. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 125. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
TABLE 126. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 127. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 128. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 129. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 130. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 131. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 132. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 133. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 134. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 135. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 137. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 138. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 208. UNITED KINGDOM DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 210. UNITED KINGDOM DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 212. GERMANY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 213. GERMANY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 214. GERMANY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 215. GERMANY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 216. GERMANY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
TABLE 217. GERMANY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 218. GERMANY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 219. GERMANY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 220. GERMANY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 221. GERMANY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 222. GERMANY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 223. GERMANY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 224. GERMANY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 225. GERMANY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 226. GERMANY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. GERMANY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 228. GERMANY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 229. GERMANY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 230. FRANCE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 231. FRANCE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 232. FRANCE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 233. FRANCE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 234. FRANCE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
TABLE 235. FRANCE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 236. FRANCE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 237. FRANCE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 238. FRANCE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 239. FRANCE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 240. FRANCE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 241. FRANCE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 242. FRANCE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 243. FRANCE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 244. FRANCE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. FRANCE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 246. FRANCE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 247. FRANCE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 248. RUSSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 249. RUSSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 250. RUSSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 251. RUSSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 252. RUSSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
TABLE 253. RUSSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 254. RUSSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 255. RUSSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 256. RUSSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 257. RUSSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 258. RUSSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 266. ITALY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 267. ITALY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 268. ITALY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 269. ITALY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 270. ITALY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
TABLE 271. ITALY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 272. ITALY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 273. ITALY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 274. ITALY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 275. ITALY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 276. ITALY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 277. ITALY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 278. ITALY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 279. ITALY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 280. ITALY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. ITALY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 282. ITALY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 283. ITALY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 284. SPAIN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 285. SPAIN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 286. SPAIN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
TABLE 287. SPAIN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
TABLE 288. SPAIN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
TABLE 289. SPAIN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
TABLE 290. SPAIN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 291. SPAIN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
TABLE 292. SPAIN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 293. SPAIN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 294. SPAIN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 295. SPAIN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
TABLE 296. SPAIN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 297. SPAIN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 298. SPAIN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. SPAIN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
TABLE 300. SPAIN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
TABLE 301. SPAIN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES DRUG DISCOVERY OUTSOURCING MARKET SIZ

Companies Mentioned

The companies profiled in this Drug Discovery Outsourcing market report include:
  • Agilent Technologies Inc.
  • Aragen Life Sciences Ltd.
  • BPS Bioscience, Inc.
  • Celentyx Ltd.
  • Charles River Laboratories International, Inc.
  • Covance, Inc.
  • Crown Bioscience, Inc.
  • Curia Global, Inc.
  • Dalton Pharma Services
  • Eurofins Scientific
  • Evotec SE
  • Explicyte
  • GenScript Biotech Corporation
  • HD Biosciences Co., Ltd.
  • IQVIA
  • Jubilant Biosys Ltd.
  • Laboratory Corporation of America Holdings
  • Merck & Co., Inc.
  • Oncodesign Services
  • Personalis, Inc.
  • Pfizer Inc.
  • PPD Inc.
  • Promega Corporation
  • Revvity Discovery Limited
  • Sanofi S.A.
  • STC Biologics Inc.
  • Syngene International Ltd.
  • TCG Lifesciences Pvt. Limited
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.

Methodology

Loading
LOADING...

Table Information